| Trial ID: | L0910 |
| Source ID: | ISRCTN33414972
|
| Associated Drug: |
Pioglitazone
|
| Title: |
Mechanisms of action of hypoglycemic drugs in nonalcoholic fatty liver disease (NAFLD): elucidation of its association with 'inflammation'
|
| Acronym: |
--
|
| Status: |
Not Recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Nonalcoholic fatty liver disease, type 2 diabetes <br>Nutritional, Metabolic, Endocrine <br>Non-insulin-dependent diabetes mellitus
|
| Interventions: |
Patients are divided into NAFLD and non-NAFLD groups by abdominal ultrasound. <br><br>The patients with NAFLD will be then randomly allocated to receive either pioglitazone (30 mg/day), metformin (1 g/day), sitagliptin (50 mg/day) or a non-antidiabetic dr
|
| Outcome Measures: |
Differences between baseline and end-of-treatment liver to spleen (L/S) ratios determined by CT and physical findings (blood pressure, body mass index and waist circumference) will be measured in each group.<br>Blood samples will be obtained to measure concentrations of aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transpeptidase (GGT), cholinesterase, fasting plasma glucose, fasting insulin, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol (HDL-C), triglycerides, non-esterified fatty acids (NEFA), high-sensitivity C-reactive protein (hsCRP), soluble tumor necrosis factor receptors 1 (sTNFR-1), and 2 (sTNFR-2), high-molecular-weight (HMW) adiponectin, and ferritin.No secondary outcome measures
|
| Sponsor/Collaborators: |
University of Ryukyus (Japan)
|
| Gender: |
Male
|
| Age: |
nannan
|
| Phases: |
Not applicable
|
| Enrollment: |
800
|
| Study Type: |
Interventional
|
| Study Designs: |
Randomized parallel group trial (Treatment)
|
| Start Date: |
16/12/2013
|
| Completion Date: |
--
|
| Results First Posted: |
--
|
| Last Update Posted: |
27 February 2017
|
| Locations: |
Japan
|
| URL: |
http://isrctn.com/ISRCTN33414972
|
